Gan & Lee Pharmaceuticals Co., Ltd. Class ASSE: 603087

Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection

· Issued by Gan & Lee Pharmaceuticals Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment